JP2016504361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504361A5 JP2016504361A5 JP2015550497A JP2015550497A JP2016504361A5 JP 2016504361 A5 JP2016504361 A5 JP 2016504361A5 JP 2015550497 A JP2015550497 A JP 2015550497A JP 2015550497 A JP2015550497 A JP 2015550497A JP 2016504361 A5 JP2016504361 A5 JP 2016504361A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- depressive disorder
- pregna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 208000020401 Depressive disease Diseases 0.000 claims 9
- 239000007922 nasal spray Substances 0.000 claims 5
- 229940097496 nasal spray Drugs 0.000 claims 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000027288 circadian rhythm Effects 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261747167P | 2012-12-28 | 2012-12-28 | |
| US61/747,167 | 2012-12-28 | ||
| PCT/US2013/076497 WO2014105620A1 (en) | 2012-12-28 | 2013-12-19 | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504361A JP2016504361A (ja) | 2016-02-12 |
| JP2016504361A5 true JP2016504361A5 (enExample) | 2017-02-02 |
| JP6283689B2 JP6283689B2 (ja) | 2018-02-21 |
Family
ID=49950051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015550497A Active JP6283689B2 (ja) | 2012-12-28 | 2013-12-19 | うつ病性障害の処置のためのプレグナ‐４‐エン‐２０‐イン‐３‐オンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10322138B2 (enExample) |
| EP (1) | EP2938346B1 (enExample) |
| JP (1) | JP6283689B2 (enExample) |
| KR (1) | KR102209475B1 (enExample) |
| CN (1) | CN104936600B (enExample) |
| AU (1) | AU2013371025B2 (enExample) |
| CA (1) | CA2894686C (enExample) |
| DK (1) | DK2938346T3 (enExample) |
| ES (1) | ES2625778T3 (enExample) |
| MX (1) | MX369774B (enExample) |
| WO (1) | WO2014105620A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| PL3955933T3 (pl) * | 2019-04-15 | 2024-04-29 | Vistagen Therapeutics, Inc. | Leczenie migreny |
| WO2024254005A1 (en) | 2023-06-04 | 2024-12-12 | Vistagen Therapeutics, Inc. | 1,3,5(10),16-estratetraen-3-yl acetate for use in improving psychomotor or cognitive performance |
| US20250312356A1 (en) * | 2024-04-08 | 2025-10-09 | Vistagen Therapeutics, Inc. | Treatment of dysmenorrhea |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5303703A (en) | 1991-10-03 | 1994-04-19 | Pherin Corporation | Combined neuroepithelial sample delivery electrode device and methods of using same |
| ES2210243T3 (es) * | 1993-06-15 | 2004-07-01 | Pherin Corporation | Esteroides de androstano utiles como iniciadores del cambio de la funcion hipotalamica humana, composiciones farmaceuticas y procedimientos asociados. |
| US6057439A (en) | 1994-08-04 | 2000-05-02 | Pherin Corporation | Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety |
| US5563131A (en) * | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| US6066627A (en) | 1994-08-04 | 2000-05-23 | Pherin Corporation | Steroids as neurochemical initiators of change in human blood levels of LH |
| US5994333A (en) * | 1994-08-04 | 1999-11-30 | Pherin Corporation | Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| US6331534B1 (en) | 1994-08-04 | 2001-12-18 | Pherin Pharmaceuticals, Inc. | Steroids as neurochemical stimulators of the VNO to alleviate pain |
| US6117860A (en) | 1994-08-04 | 2000-09-12 | Pherin Pharmaceuticals, Inc. | Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia |
| ATE342721T1 (de) * | 1996-07-23 | 2006-11-15 | Pherin Pharm Inc | Steroide als neurochemische stimulatoren des nasenraumes zur linderung der prämenstrualen symptome |
| US20020123138A1 (en) | 2000-11-30 | 2002-09-05 | Jian Zhang | Human VNO receptor (R1) |
| US20030045514A1 (en) | 2001-05-03 | 2003-03-06 | Louis Monti | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors |
-
2013
- 2013-12-19 KR KR1020157020176A patent/KR102209475B1/ko active Active
- 2013-12-19 ES ES13819136.6T patent/ES2625778T3/es active Active
- 2013-12-19 CN CN201380062351.9A patent/CN104936600B/zh active Active
- 2013-12-19 EP EP13819136.6A patent/EP2938346B1/en active Active
- 2013-12-19 MX MX2015008454A patent/MX369774B/es active IP Right Grant
- 2013-12-19 CA CA2894686A patent/CA2894686C/en active Active
- 2013-12-19 US US14/134,906 patent/US10322138B2/en active Active
- 2013-12-19 JP JP2015550497A patent/JP6283689B2/ja active Active
- 2013-12-19 WO PCT/US2013/076497 patent/WO2014105620A1/en not_active Ceased
- 2013-12-19 AU AU2013371025A patent/AU2013371025B2/en active Active
- 2013-12-19 DK DK13819136.6T patent/DK2938346T3/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013155188A5 (enExample) | ||
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| JP2015512418A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2013541583A5 (enExample) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| BR112015009504A2 (pt) | inibidores de rock | |
| RU2015103107A (ru) | Комбинированная композиция | |
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2016504361A5 (enExample) | ||
| MX2015014939A (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| Zabegalov et al. | Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
| MY180772A (en) | Novel therapeutic mirtazapine combinations for use in pain disorders | |
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности | |
| MX2018005876A (es) | Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. | |
| JP2015533131A5 (enExample) | ||
| CN104667073A (zh) | 治疗神经衰弱的中药 |